Log in

NASDAQ:MTEM - Molecular Templates Stock Price, Forecast & News

+0.40 (+3.38 %)
(As of 12/8/2019 08:58 AM ET)
Today's Range
Now: $12.24
50-Day Range
MA: $9.30
52-Week Range
Now: $12.24
Volume265,268 shs
Average Volume432,250 shs
Market Capitalization$452.51 million
P/E RatioN/A
Dividend YieldN/A
Molecular Templates, Inc, a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MTEM



Sales & Book Value

Annual Sales$13.28 million
Book Value$2.75 per share


Net Income$-30,290,000.00
Net Margins-289.90%


Market Cap$452.51 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive MTEM News and Ratings via Email

Sign-up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.

Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Shares of Molecular Templates reverse split on the morning of Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

How were Molecular Templates' earnings last quarter?

Molecular Templates Inc (NASDAQ:MTEM) posted its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.19. The biotechnology company earned $3.62 million during the quarter, compared to the consensus estimate of $6 million. Molecular Templates had a negative net margin of 289.90% and a negative return on equity of 44.86%. View Molecular Templates' Earnings History.

When is Molecular Templates' next earnings date?

Molecular Templates is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Molecular Templates.

What price target have analysts set for MTEM?

5 brokerages have issued 12 month price targets for Molecular Templates' shares. Their forecasts range from $12.00 to $15.00. On average, they anticipate Molecular Templates' share price to reach $14.25 in the next year. This suggests a possible upside of 16.4% from the stock's current price. View Analyst Price Targets for Molecular Templates.

What is the consensus analysts' recommendation for Molecular Templates?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Molecular Templates.

What are Wall Street analysts saying about Molecular Templates stock?

Here are some recent quotes from research analysts about Molecular Templates stock:
  • 1. According to Zacks Investment Research, "Molecular Templates Inc. is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies for the treatment of cancers and other serious diseases. Molecular Templates Inc., formerly known as Threshold Pharmaceuticals Inc., is headquartered in Austin, United States. " (11/19/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "Initiating coverage with Outperform rating and $15 PT. We believe Bodies (ETB) platform offers a differentiated MOA based on forced internalization of antibody fragments directly to ribosomes through the Shiga-Like toxin A mechanism of action resulting in disruption of protein synthesis and direct cell-kill. We expect this novel MOA to offer clinical advantages in: 1) monotherapy in refractory setting when receptor expression is maintained despite resistance to prior treatments targeting the receptor (i.e., 2) combination therapy for frontline as a more potent substitute for a antibody therapeutics, and 3) novel targets not amenable to antibodies due to challenges to internalization. We anticipate ETBs will be attractive to pharma and expect partnerships to contribute to 2019-20 news flow." (12/10/2018)

Has Molecular Templates been receiving favorable news coverage?

News articles about MTEM stock have trended somewhat positive this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Molecular Templates earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Molecular Templates.

Are investors shorting Molecular Templates?

Molecular Templates saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 854,500 shares, an increase of 5.8% from the October 31st total of 807,500 shares. Based on an average trading volume of 131,300 shares, the short-interest ratio is currently 6.5 days. Approximately 4.3% of the company's shares are short sold. View Molecular Templates' Current Options Chain.

Who are some of Molecular Templates' key competitors?

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Alibaba Group (BABA), SLS International (SLS), Walt Disney (DIS), CEL-SCI (CVM), Corbus Pharmaceuticals (CRBP), TG Therapeutics (TGTX) and ACADIA Pharmaceuticals (ACAD).

Who are Molecular Templates' key executives?

Molecular Templates' management team includes the folowing people:
  • Dr. Eric E. Poma, CEO, Chief Scientific Officer & Director (Age 47)
  • Ms. Jason S Kim, Pres & COO (Age 44)
  • Mr. Adam D. Cutler B.A., Chief Financial Officer (Age 44)
  • Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 52)
  • Dr. Jack Higgins Ph.D., Exec. VP of Operations & Head of Manufacturing (Age 39)

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (0.62%), Bowling Portfolio Management LLC (0.14%), Public Employees Retirement System of Ohio (0.12%), Russell Investments Group Ltd. (0.09%), California Public Employees Retirement System (0.06%) and Squarepoint Ops LLC (0.03%). Company insiders that own Molecular Templates stock include Associates LLC Cdk, David Hirsch, Longitude Capital Partners Iii and Scott D Morenstein. View Institutional Ownership Trends for Molecular Templates.

Which institutional investors are selling Molecular Templates stock?

MTEM stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Molecular Templates.

Which institutional investors are buying Molecular Templates stock?

MTEM stock was acquired by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC, Public Employees Retirement System of Ohio, Russell Investments Group Ltd., State Street Corp, Squarepoint Ops LLC, Tower Research Capital LLC TRC and California Public Employees Retirement System. Company insiders that have bought Molecular Templates stock in the last two years include Associates LLC Cdk, David Hirsch, Longitude Capital Partners Iii and Scott D Morenstein. View Insider Buying and Selling for Molecular Templates.

How do I buy shares of Molecular Templates?

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $12.24.

How big of a company is Molecular Templates?

Molecular Templates has a market capitalization of $452.51 million and generates $13.28 million in revenue each year. The biotechnology company earns $-30,290,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Molecular Templates employs 68 workers across the globe.View Additional Information About Molecular Templates.

What is Molecular Templates' official website?

The official website for Molecular Templates is http://www.mtem.com/.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]

MarketBeat Community Rating for Molecular Templates (NASDAQ MTEM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  270 (Vote Underperform)
Total Votes:  560
MarketBeat's community ratings are surveys of what our community members think about Molecular Templates and other stocks. Vote "Outperform" if you believe MTEM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTEM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel